Does Rallies show Form 4 insider transactions for BEAM?

Yes. Rallies tracks BEAM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BEAM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BEAM. It does not provide personalized investment advice.

BEAM (Beam Therapeutics Inc. Common Stock) Stock Analysis - Insider Trades

Beam Therapeutics Inc. Common Stock (BEAM) is a publicly traded Healthcare sector company. As of May 20, 2026, BEAM trades at $27.12 with a market cap of $2.76B and a P/E ratio of -53.82. BEAM moved +3.06% today. Year to date, BEAM is -2.98%; over the trailing twelve months it is +49.14%. Its 52-week range spans $13.53 to $36.44. Analyst consensus is strong buy with an average price target of $49.91. Rallies surfaces BEAM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BEAM stock inside the company?

Recent BEAM insider activity includes Evans John M. sold 30.08K, Simon Amy sold 6.70K, Cavanagh Bethany J sold 3.24K, Bellon Christine sold 5.96K, and Ciaramella Giuseppe sold 11.81K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BEAM Key Metrics

Key financial metrics for BEAM
Metric	Value
Price	$27.12
Market Cap	$2.76B
P/E Ratio	-53.82
EPS	$-0.50
Dividend Yield	0.23%
52-Week High	$36.44
52-Week Low	$13.53
Volume	1.79M
Avg Volume	0
Revenue (TTM)	$164.01M
Net Income	$-65.04M
Gross Margin	0.00%

Recent BEAM Insider Trades

Evans John M. sold 30.08K (~$739.32K) on Apr 1, 2026.
Simon Amy sold 6.70K (~$164.69K) on Apr 1, 2026.
Cavanagh Bethany J sold 3.24K (~$79.69K) on Apr 1, 2026.
Bellon Christine sold 5.96K (~$146.40K) on Apr 1, 2026.
Ciaramella Giuseppe sold 11.81K (~$290.29K) on Apr 1, 2026.

Latest BEAM News

Beam Therapeutics Reports Durable Phase 1/2 Safety and Efficacy in 29 Patients — May 18, 2026
Beam Therapeutics Backs AlphaDetect with Inaugural Sponsorship to Scale Alpha-1 Testing — May 13, 2026
Beam Therapeutics’ $1.2B Cash Runway Fuels 2026 BLA for Sickle Cell Drug — May 13, 2026
Beam Therapeutics Raises Price Target to $26 and Eyes BLA Submission — Feb 28, 2026
Beam Therapeutics Q4 Loss Shrinks to $0.10, Revenue Soars 9x to $114M — Feb 24, 2026

BEAM Analyst Consensus

12 analysts cover BEAM: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $49.91.

Common questions about BEAM

Who is trading BEAM stock inside the company?: Recent BEAM insider activity includes Evans John M. sold 30.08K, Simon Amy sold 6.70K, Cavanagh Bethany J sold 3.24K, Bellon Christine sold 5.96K, and Ciaramella Giuseppe sold 11.81K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BEAM?: Yes. Rallies tracks BEAM insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BEAM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BEAM. It does not provide personalized investment advice.